

# CONGRESSO REGIONALE **SID-AMD** LAZIO

**DIABETOLOGIA 2024:**  
NUOVI SCENARI CLINICI  
E PROSPETTIVE TERAPEUTICHE



ROMA, 29-30 NOVEMBRE 2024

UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA

NOVITÀ FLASH DAGLI STUDI CLINICI

**RIACE**

**Martina Vitale**

*UOC Medicina Specialistica Endocrino-Metabolica –  
Azienda Ospedaliero-Universitaria Sant'Andrea  
Roma*

*Dipartimento di Medicina Clinica e Molecolare –  
Sapienza Università di Roma*

- RIACE is a multicentre observational, prospective cohort study that was conducted in 19 hospital diabetes centers in Italy
- OBJECTIVES:
  - eGFR as independent predictor of CVD morbidity and mortality in T2DM
  - The prevalence of eGFR reduction and its association with cardiovascular risk factors and albuminuria
- The RIACE population consists of 15,933 Caucasian patients with type 2 diabetes recruited in years 2007–2008
  - Exclusion criteria were dialysis or renal transplantation
  - 160 subjects were excluded due to missing or implausible values

Data from the remaining 15,773 patients were analyzed






Age:  $66.0 \pm 10.3$  years (median 67 years)

Sex: 56.8% male and 43.2% female

Diabetes duration:  $13.2 \pm 10.2$  years (median 11 years)

# The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study

## Clinical significance of nonalbuminuric renal impairment in type 2 diabetes



# The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study

## Clinical significance of nonalbuminuric renal impairment in type 2 diabetes

	No	↑ Alb	↓ eGFR	↑ Alb & ↓ eGFR	p
Variable	Overall	Alb <sup>-</sup> /eGFR <sup>-</sup>	Alb <sup>+</sup> /eGFR <sup>-</sup>	Alb <sup>-</sup> /eGFR <sup>+</sup>	
n (%)	15,656 (100)	9984 (63.77)	2966 (18.94)	1476 (9.43)	1230 (7.86)
Age, years	66.6 ± 10.3	64.8 ± 10.0	66.0 ± 10.1	74.4 ± 8.1	73.2 ± 9.1 <0.0001
Sex, n (%)					<0.0001
Female	6754 (43.14)	4510 (45.17)	891 (30.04)	889 (60.23)	464 (37.72)
Male	8902 (56.86)	5474 (54.83)	2075 (69.96)	587 (39.77)	766 (62.28)
Smoking status, n (%)					<0.0001
Never	8849 (56.52)	5810 (58.19)	1449 (48.85)	935 (63.35)	655 (53.25)
Former	4407 (28.15)	2644 (26.48)	926 (31.22)	417 (28.25)	420 (34.15)
Current	2400 (15.33)	1530 (15.32)	591 (19.93)	124 (8.40)	155 (12.60)
Diabetes duration, years	13.2 ± 10.2	11.9 ± 9.6	13.8 ± 10.0	16.4 ± 11.3	18.3 ± 10.9 <0.0001
HbA <sub>1c</sub> , mmol/mol	59.0 ± 16.4	57.4 ± 15.4	62.6 ± 18.3	59.4 ± 15.8	62.3 ± 18.8 <0.0001
HbA <sub>1c</sub> , %	7.55 ± 1.50	7.40 ± 1.41	7.88 ± 1.68	7.58 ± 1.45	7.85 ± 1.65


# The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study

## Clinical significance of nonalbuminuric renal impairment in type 2 diabetes

Variable	No	↑ Alb	↓ eGFR	↑ Alb & ↓ eGFR	p
Overall					
Anti-hypertensive therapy, n (%)	11,072 (70.72)	6347 (63.57)	2339 (78.86)	1270 (86.04)	1116 (90.73) <0.0001
RAS blockers, n (%)	9340 (59.66)	5258 (52.66)	2051 (69.15)	1072 (72.63)	959 (77.97) <0.0001
Hypertension, n (%)	13,096 (83.65)	7906 (79.19)	2650 (89.35)	1371 (92.89)	1169 (95.04) <0.0001
Diabetic retinopathy, n (%)					<0.0001
No	12,189 (77.86)	8273 (82.86)	2072 (69.86)	1129 (76.49)	715 (58.13)
Non-advanced	1947 (12.44)	1065 (10.67)	447 (15.07)	195 (13.21)	240 (19.51)
Advanced	1520 (9.71)	646 (6.47)	447 (15.07)	152 (10.30)	275 (22.36)
CVD, n (%)					
Any	3620 (23.12)	1770 (17.73)	793 (26.74)	495 (33.54)	562 (45.69) <0.0001
Acute myocardial infarction	1742 (11.13)	880 (8.81)	344 (11.60)	258 (17.48)	260 (21.14) <0.0001
Coronary revascularisation	1579 (10.09)	809 (8.10)	320 (10.79)	230 (15.58)	220 (17.89) <0.0001
Any coronary event	2396 (15.30)	1218 (12.20)	478 (16.12)	351 (23.78)	349 (28.37) <0.0001
Stroke	513 (3.28)	231 (2.31)	123 (4.15)	70 (4.74)	89 (7.24) <0.0001
Carotid revascularisation	856 (5.47)	370 (3.71)	191 (6.44)	129 (8.74)	166 (13.50) <0.0001
Any cerebrovascular event	1292 (8.25)	573 (5.74)	296 (9.98)	187 (12.67)	236 (19.19) <0.0001
Ulcer/gangrene/amputation	556 (3.55)	197 (1.97)	164 (5.53)	70 (4.74)	125 (10.16) <0.0001
Lower limb revascularisation	450 (2.87)	178 (1.78)	102 (3.44)	68 (4.61)	102 (8.29) <0.0001

# The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study

Non-albuminuric renal impairment is a **strong predictor of mortality** in individuals with T2D



**Death rate 31.0 per 1000 person-years**


# The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study

Non-albuminuric renal impairment is a **strong predictor of mortality** in individuals with T2D

**Table 2** Mortality rates according to DKD phenotype and KDIGO risk category and subcategory

Characteristic	n	Events	Per cent events	Events per 1000 person-years (95% CI), unadjusted	p
DKD phenotype					
No ↑ Alb	9984	1536	15.38	19.87 (18.87, 20.86)	<0.0001
↑ Alb ↓ eGFR	2966	793	26.74	36.79 (34.23, 39.35)	
↓ eGFR	1476	604	40.92	61.49 (56.59, 66.40)	
↑ Alb & ↓ eGFR	1230	669	54.39	90.25 (83.41, 97.08)	

↑ Alb  
↓ eGFR  
↑ Alb & ↓ eGFR



**ORIGINAL ARTICLE****Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes**Orsi E et al. *Diabetes Obes Metab* 2018**Open Access****ORIGINAL INVESTIGATION****Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study**Orsi E et al. *Cardiovasc Diabetol* 2021**RESEARCH ARTICLE****Open Access****Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study**Solini A et al. *BMC Medicine* 2019**Open Access****RESEARCH****Open Access****Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes**Orsi E et al. *Cardiovasc Diabetol* 2022**Open access****Original research****BMJ Open Diabetes Research & Care****Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study**Penno G et al. *BMJ Open Diab Res Care* 2020**ORIGINAL ARTICLE****Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study**Orsi E et al. *Acta Diabetol* 2022**RESEARCH ARTICLE****Open Access****Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study**Penno G et al. *BMC Medicine* 2021**Original article****Retinopathy as an independent predictor of all-cause mortality in individuals with type 2 diabetes**Orsi E et al. *Diabetes Metab* 2023

RESEARCH

Open Access



# Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study

Martina Vitale<sup>1</sup>, Emanuela Orsi<sup>2</sup>, Anna Solini<sup>3</sup>, Monia Garofolo<sup>4</sup>, Veronica Resi<sup>2</sup>, Enzo Bonora<sup>5</sup>, Cecilia Fondelli<sup>6</sup>, Roberto Trevisan<sup>7</sup>, Monica Vedovato<sup>8</sup>, Giuseppe Penno<sup>4</sup> and Giuseppe Pugliese<sup>1\*</sup>

# Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes

**Table 1** Baseline clinical features of study participants by history of diabetic foot

Variables	History of diabetic foot	
	No	Yes
N (%)	14,878 (94.3)	895 (5.7)
Ulcer/gangrene	–	532 (59.4)
Amputation	–	153 (17.1)
Minor	–	129 (14.4)
Major	–	24 (2.7)
Ulcer/gangrene/amputation	–	565 (63.1)
Lower limb revascularization	–	456 (50.9)
Endovascular	–	192 (21.5)
Surgical	–	245 (27.4)
Both	–	19 (2.1)


# Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes

**Table 2** Mortality rates in study participants by history of diabetic foot, ulcer/gangrene and/or amputation, and ulcer/gangrene/amputation and/or lower limb revascularization

	N	Events	Percent events	Events per 1,000 patient-years (95% CI), unadjusted	P	Events per 1,000 patient-years (95% CI), age- & sex-adjusted	p
History of diabetic foot no	14,773	3,186	21.6	28.78 (27.80–29.80)	Ref.	12.50 (11.10–14.09)	Ref.
History of diabetic foot yes	883	416	47.1	76.83 (69.79–84.58)	<0.0001	25.51 (21.84–29.79)	<0.0001
Ulcer/gangrene no – Amputation no	15,100	3,324	22.0	29.47 (28.49–30.49)	Ref.	12.53 (11.12–14.12)	Ref.
Ulcer/gangrene yes – Amputation no	407	198	48.6	81.27 (70.70–93.42)	<0.0001	25.05 (20.87–30.07)	<0.0001
Ulcer/gangrene no – Amputation yes	33	16	48.5	77.46 (47.45–126.43)	0.013	32.48 (19.59–53.84)	0.014
Ulcer/gangrene yes – Amputation yes	116	64	55.2	94.01 (73.58–120.11)	<0.0001	36.89 (27.96–486.7)	<0.0001
Ulcer/gangrene/amput no – Revasc no	14,773	3,186	21.6	28.78 (27.80–29.80)	Ref.	12.50 (11.10–14.09)	Ref.
Ulcer/gangrene/amput yes – Revasc no	433	203	46.9	76.23 (66.43–87.47)	<0.0001	26.31 (21.95–31.54)	<0.0001
Ulcer/gangrene/amput no – Revasc yes	327	138	42.2	66.01 (55.87–78.00)	<0.0001	21.74 (17.65–26.78)	<0.0001
Ulcer/gangrene/amput yes – Revasc yes	123	75	61.0	113.50 (90.51–142.33)	<0.0001	33.46 (25.80–43.39)	<0.0001

CI=confidence interval


# Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes



Kaplan-Meier analysis (A) and Cox proportional hazards regression, adjusted for age and sex (B),  
plus cardiovascular risk factors (C), plus complications and comorbidities (D)

Vitale M et al. Cardiovasc Diabetol. 2024 Jan 13;23(1):34.

# Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes



Kaplan-Meier analysis (A) and Cox proportional hazards regression, adjusted for age and sex (B),  
plus cardiovascular risk factors (C), plus complications and comorbidities (D)

Vitale M et al. Cardiovasc Diabetol. 2024 Jan 13;23(1):34.

RESEARCH

Open Access



Independent association of history of diabetic foot with all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study

Martina Vitale<sup>1</sup>, Emanuela Orsi<sup>2</sup>, Anna Solini<sup>3</sup>, Monia Garofolo<sup>4</sup>, Veronica Resi<sup>2</sup>, Enzo Bonora<sup>5</sup>, Cecilia Fondelli<sup>6</sup>, Roberto Trevisan<sup>7</sup>, Monica Vedovato<sup>8</sup>, Giuseppe Penno<sup>4</sup> and Giuseppe Pugliese<sup>1\*</sup>

## TAKE HOME MESSAGES - 1

- In patients with type 2 diabetes from the RIACE cohort, an **history of diabetic foot event**, including ulcer/gangrene, amputation, and lower limb revascularization, was associated with a ~ 50% increased risk of subsequent death from any cause, independent of CVD risk factors, other complications and severe comorbidities
- The association with mortality was greatest for **amputation**
- The impact of **revascularization** alone was relatively modest

OXFORD

*QJM: An International Journal of Medicine*, 2024, **117**(7), 495–502

<https://doi.org/10.1093/qjmed/hcae012>

Advance Access Publication Date: 10 January 2024

Original Article


# Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes

A. Solini  <sup>1</sup>, E. Orsi<sup>2</sup>, M. Vitale<sup>3</sup>, M. Garofolo<sup>4</sup>, V. Resi<sup>2</sup>, E. Bonora<sup>5</sup>, C. Fondelli<sup>6</sup>, R. Trevisan<sup>7</sup>, M. Vedovato<sup>8</sup>, A. Nicolucci<sup>9</sup>, G. Penno<sup>4</sup> and G. Pugliese  <sup>3,\*</sup>, for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group<sup>†</sup>

# Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes

**Table 1.** Baseline clinical features of study participants by ePWV quartiles

Variables	I	II	III	IV	P
N (%)	3914	3914	3915	3913	
ePWV, m·s <sup>-1</sup> (range)	$8.37 \pm 0.81$ (4.89–9.45)	$10.12 \pm 0.37$ (9.46–10.74)	$11.40 \pm 0.40$ (10.74–12.13)	$13.33 \pm 0.98$ (12.13–19.74)	
Deaths, n (%)	357 (9.1)	587 (15.0)	929 (23.7)	1729 (44.2)	<0.0001





Kaplan-Meier analysis according to ePWV quartiles.

Number and percentage of deaths, death rates as events per 1000 patient-years (95% CI)

Solini A et al. QJM. 2024 Jul 1;117(7):495-502.




# Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes



Cox proportional hazards regression, unadjusted (**A**) adjusted for sex, age, BP (**B**), plus other CVD risk factors (**C**), plus complications and comorbidities (**D**)

Solini A et al. QJM. 2024 Jul 1;117(7):495-502.

# Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes



Marginal improvement provided by ePWV in the prediction of all-cause death over sex, age, BP (**A, Model 1**), plus other CVD risk factors (**B, Model 2**), plus complications and comorbidities (**C, Model 3**)

## Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes

A. Solini <sup>1</sup>, E. Orsi<sup>2</sup>, M. Vitale<sup>3</sup>, M. Garofolo<sup>4</sup>, V. Resi<sup>2</sup>, E. Bonora<sup>5</sup>, C. Fondelli<sup>6</sup>, R. Trevisan<sup>7</sup>, M. Vedovato<sup>8</sup>, A. Nicolucci<sup>9</sup>, G. Pennò<sup>4</sup> and G. Pugliese <sup>3,\*</sup>, for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group<sup>†</sup>

## TAKE HOME MESSAGES - 2

- This analysis of the RIACE cohort of individuals with type 2 diabetes shows that **ePWV** is **associated** with all-cause mortality **independently** of complications, comorbidities and traditional CVD risk factors
- ePWV improved **prediction** of mortality risk over CVD risk factors, complications and comorbidities, though the net difference was modest
- ePWV may represent a **simple and inexpensive tool** for risk stratification of diabetic patients and identification of those who deserve a more aggressive treatment

Acta Diabetologica  
<https://doi.org/10.1007/s00592-024-02294-1>

ORIGINAL ARTICLE



## Association between age at diagnosis and all-cause mortality in type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study

Martina Vitale<sup>1</sup> · Emanuela Orsi<sup>2</sup> · Anna Solini<sup>3</sup> · Monia Garofolo<sup>4</sup> · Valeria Grancini<sup>2</sup> · Enzo Bonora<sup>5</sup> · Cecilia Fondelli<sup>6</sup> · Roberto Trevisan<sup>7</sup> · Monica Vedovato<sup>8</sup> · Giuseppe Penno<sup>4</sup> · Antonio Nicolucci<sup>9</sup> · Giuseppe Pugliese<sup>1</sup> · for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group\*

# Association between age at diagnosis and all-cause mortality in type 2 diabetes


**Table 1** Baseline clinical features of study participants by quartiles of age at type 2 diabetes diagnosis

Variables	I	II	III	IV	P
N (%)	3915	3914	3913	3914	
Age at type 2 diabetes diagnosis, years (range)	$39.6 \pm 4.7$ (20.5–45.9)	$49.8 \pm 2.2$ (45.9–53.5)	$57.2 \pm 2.2$ (53.5–61.2)	$67.8 \pm 5.3$ (61.2–93.5)	
Age, years	$59.5 \pm 11.3$	$65.0 \pm 9.5$	$67.7 \pm 7.5$	$74.2 \pm 6.3$	<0.0001
Diabetes duration, years	$19.8 \pm 10.3$	$15.1 \pm 9.6$	$10.6 \pm 7.5$	$6.5 \pm 5.3$	<0.0001

# Association between age at diagnosis and all-cause mortality in type 2 diabetes

**Table 3** Mortality rates in study participants by quartiles of age at type 2 diabetes diagnosis

Quartile	N	Events	Percent events	Events per 1,000 patient-years (95% CI), unadjusted	P
I	3,915	663	16.9	22.03 (20.41–23.77)	Ref
II	3,914	826	21.1	28.22 (26.36–30.21)	<0.0001
III	3,913	838	21.4	28.57 (26.70–30.57)	<0.0001
IV	3,914	1,275	32.6	46.54 (44.06–49.17)	<0.0001




Kaplan-Meier analysis (**A**) and unadjusted Cox proportional hazards regression (**B**) by quartiles of age at type 2 diabetes diagnosis

Vitale M et al. Acta Diabetol. 2024 Sep;61(9):1107-1116.

# Association between age at diagnosis and all-cause mortality in type 2 diabetes

**Table 3** Mortality rates in study participants by quartiles of age at type 2 diabetes diagnosis



Quartile	N	Events	Percent events	Events per 1,000 patient-years (95% CI), unadjusted	P	Events per 1,000 patient-years (95% CI), age- & sex-adjusted	P
I	3,915	663	16.9	22.03 (20.41–23.77)	Ref	14.98 (13.07–17.18)	Ref
II	3,914	826	21.1	28.22 (26.36–30.21)	<0.0001	13.28 (11.64–15.15)	0.023
III	3,913	838	21.4	28.57 (26.70–30.57)	<0.0001	11.74 (10.29–13.40)	<0.0001
IV	3,914	1,275	32.6	46.54 (44.06–49.17)	<0.0001	11.40 (9.99–13.00)	<0.0001



Cox proportional hazards regression, adjusted for sex, age (A)

Vitale M et al. Acta Diabetol. 2024 Sep;61(9):1107-1116.

# Association between age at diagnosis and all-cause mortality in type 2 diabetes



Cox proportional hazards regression, adjusted for sex, age (**A**), plus diabetes duration (**B**),  
plus other risk factors (**C**), plus complications and comorbidities (**D**)

Vitale M et al. Acta Diabetol. 2024 Sep;61(9):1107-1116.



## Association between age at diagnosis and all-cause mortality in type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study

Martina Vitale<sup>1</sup> · Emanuela Orsi<sup>2</sup> · Anna Solini<sup>3</sup> · Monia Garofolo<sup>4</sup> · Valeria Grancini<sup>2</sup> · Enzo Bonora<sup>5</sup> · Cecilia Fondelli<sup>6</sup> · Roberto Trevisan<sup>7</sup> · Monica Vedovato<sup>8</sup> · Giuseppe Penno<sup>4</sup> · Antonio Nicolucci<sup>9</sup> · Giuseppe Pugliese<sup>1</sup> · for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group\*

## TAKE HOME MESSAGES - 3

- This analysis of the RIACE cohort showed that type 2 diabetes diagnosed in **early adulthood** was **associated with higher age- and sex-adjusted risk** of all-cause death than that occurring later in life
- However, no difference was observed when further **adjusting for diabetes duration or complications/comorbidities**
- These data point to the need for **public health policies and tailored guidelines for preventing and treating** early-onset type 2 diabetes to avoid premature morbidity and mortality from complications.

# The RIACE Study Group



## The RIACE Steering Committee

**Coordinator:** Giuseppe Pugliese

**Secretary:** Giuseppe Penno

**Scientific committee:** Anna Solini, Enzo Bonora, Emanuela Orsi, Roberto Trevisan, Luigi Laviola, Antonio Nicolucci

## Participating Diabetes Centres

1. Azienda Ospedaliera Sant'Andrea, Roma (Coordinating Centre): Giuseppe Pugliese, Lucilla Bollanti, Elena Alessi, Martina Vitale, and Tiziana Cirrito.
2. Ospedale Le Molinette, Torino: Paolo Cavallo-Perin, Gabriella Gruden, and Bartolomeo Lorenzati.
3. Ospedale San Luigi Gonzaga, Orbassano: Franco Cavalot, Mariella Trovati, Leonardo Di Martino, and Fabio Mazzaglia.
4. Ospedale San Raffaele, Milano: Giampaolo Zerbini, Valentina Martina, Silvia Maestroni, and Valentina Capuano.
5. IRCCS "Cà Granda – Ospedale Maggiore Policlinico", Milano: Emanuela Orsi, Eva Palmieri, Elena Lunati, Valeria Grancini, and Veronica Resi.
6. Ospedale San Paolo, Milano: Antonio Pontiroli, Annamaria Veronelli, and Barbara Zecchini.
7. Ospedale San Giuseppe, Milano: Maura Arosio, Laura Montefusco, and Guido Adda.
8. ASST - Ospedale Papa Giovanni XXIII, Bergamo: Roberto Trevisan, Anna Corsi, and Mascia Albizzi.
9. Ospedale Maggiore, Verona: Enzo Bonora, and Giacomo Zoppini.
10. Policlinico Universitario, Padova: Angelo Avogaro, and Monica Vedovato.
11. Ospedale Cisanello, Azienda Ospedaliero-Universitaria Pisana, Pisa: Giuseppe Penno, Laura Pucci, Daniela Lucchesi, Eleonora Russo, and Monia Garofolo.
12. Ospedale Santa Chiara, Azienda Ospedaliero-Universitaria Pisana, Pisa: Anna Solini.
13. Ospedale Le Scotte, Siena: Francesco Dotta, Cecilia Fondelli, and Laura Nigi.
14. Policlinico Umberto I, Roma: Susanna Morano, Tiziana Filardi, Irene Turinese, and Marco Rossetti.
15. Ospedale S. Maria Goretti, Latina: Raffaella Buzzetti and Chiara Foffi.
16. Ospedali Riuniti, Foggia: Mauro Cignarelli, Olga Lamacchia, Sabina Pinnelli, and Lucia Monaco.
17. Policlinico Universitario, Bari: Francesco Giorgino, Luigi Laviola, and Annalisa Natalicchio.
18. Policlinico Mater Domini, Catanzaro: Giorgio Sesti and Francesco Andreozzi.
19. Policlinico Monserrato, Cagliari: Marco Giorgio Baroni, Giuseppina Frau, and Alessandra Boi.